NewAmsterdam Pharma Company N.V.

General ticker "NAMS" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $2.6B (TTM average)

NewAmsterdam Pharma Company N.V. follows the US Stock Market performance with the rate: 49.3%.

Estimated limits based on current volatility of 3.9%: low 35.84$, high 38.77$

Factors to consider:

  • Total employees count: 68 (+134.5%) as of 2024
  • Top business risk factors: Geopolitical risks, Limited operating history, Sales and marketing challenges, Product liability, Integration challenges
  • Current price 11.3% above estimated high
  • Earnings for 9 months up through Q3 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

  • 2024-12-31 to 2025-12-31 estimated range: [14.56$, 32.20$]
  • 2025-12-31 to 2026-12-31 estimated range: [11.05$, 25.46$]

Financial Metrics affecting the NAMS estimates:

  • Negative: with PPE of -11.4 at the end of fiscal year the price was high
  • Negative: negative Operating income
  • Negative: Operating cash flow per share per price, % of -6.52 <= 0.33
  • Positive: Interest expense per share per price, % of 0 <= 0.01
  • Negative: negative Net income
  • Negative: negative Industry operating cash flow (median)
  • Negative: Shareholder equity ratio, % of 87.61 > 63.39
  • Positive: -4.48 < Investing cash flow per share per price, % of -2.59

Similar symbols

Short-term NAMS quotes

Long-term NAMS plot with estimates

Financial data

YTD 2023-12-31 2024-12-31
Operating Revenue $14.09MM $45.56MM
Operating Expenses $197.06MM $221.85MM
Operating Income $-182.97MM $-176.29MM
Non-Operating Income $6.06MM $-65.31MM
Interest Expense $6.80MM $0.00MM
R&D Expense $159.42MM $151.41MM
Income(Loss) $-176.91MM $-241.60MM
Taxes $0.03MM $-0.00MM
Profit(Loss)* $-176.94MM $-241.60MM
Stockholders Equity $288.39MM $757.50MM
Assets $347.10MM $864.62MM
Operating Cash Flow $-141.22MM $-158.56MM
Capital expenditure $0.02MM $0.67MM
Investing Cash Flow $-0.02MM $-62.85MM
Financing Cash Flow $8.91MM $659.51MM
Earnings Per Share** $-2.15 $-2.56

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.